Financial News
Articles published by Alzamend Neuro, Inc.
![](https://mms.businesswire.com/media/20240712249038/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
Alzamend Neuro Announces Reverse Stock Split
July 12, 2024
From Alzamend Neuro, Inc.
Via Business Wire
Tickers
ALZN
![](https://mms.businesswire.com/media/20220922005370/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
September 22, 2022
From Alzamend Neuro, Inc.
Via Business Wire
Tickers
ALZN
![](https://mms.businesswire.com/media/20240522362949/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20240514391603/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20240509698047/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20240507349564/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20231211519845/en/1965628/22/Next-Generation_Lithium_Product_for_PTSD_Photo_12112023.jpg)
![](https://mms.businesswire.com/media/20231120533070/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20231116713582/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20231113906125/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20231030766030/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
Alzamend Neuro Announces Reverse Stock Split
October 30, 2023
From Alzamend Neuro, Inc.
Via Business Wire
Tickers
ALZN
![](https://mms.businesswire.com/media/20231023303175/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20231002933625/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20230403005570/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20230322005380/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20230316005346/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update
March 16, 2023
From Alzamend Neuro, Inc.
Via Business Wire
Tickers
ALZN
![](https://mms.businesswire.com/media/20230126005432/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
Alzamend Neuro to Present at Sequire Biotechnology Conference
January 26, 2023
From Alzamend Neuro, Inc.
Via Business Wire
Tickers
ALZN
![](https://mms.businesswire.com/media/20230104005428/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20221228005104/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20221115005739/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
November 15, 2022
From Alzamend Neuro, Inc.
Via Business Wire
Tickers
ALZN
![](https://mms.businesswire.com/media/20221031005314/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20221005005399/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20220929005339/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20220718005402/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20220603005153/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20220517005595/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20220505005399/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20220428005560/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20220411005251/en/835633/5/Alzamend_Neuro_-_Corporate_Logo_with_R_mark_10262020.jpg.jpg)
![](https://mms.businesswire.com/media/20220404005393/en/1409269/21/Dr_Terri_Hunter-2-180x172_Headshot_04032022.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.